| Mrs Amy K O'mara, APRN, MSN, CPNP | |
|
2500 N State St, Jackson, MS 39216-4500 | |
| (601) 984-6441 | |
| (601) 815-0434 |
| Full Name | Mrs Amy K O'mara |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Neonatal, Critical Care |
| Location | 2500 N State St, Jackson, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124218490 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | R863420 (Mississippi) | Secondary |
| 363LN0005X | Nurse Practitioner - Neonatal, Critical Care | 863420 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Amy K O'mara, APRN, MSN, CPNP 2500 N State St, Jackson, MS 39216-4500 Ph: (601) 984-6441 | Mrs Amy K O'mara, APRN, MSN, CPNP 2500 N State St, Jackson, MS 39216-4500 Ph: (601) 984-6441 |
News Archive
An important new finding by University of Cincinnati researchers could help slow the transmission of HIV/AIDS and reduce pregnancies among adolescent girls in rural South Africa.
The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer in the blood.
"Job loss or the fear of it has pushed more people to use their employer-sponsored health insurance before they lose it. Major health insurers have seen their medical costs rise in recent quarters, in part because people covered by employer-sponsored plans have rushed to use services before their benefits are cut off."
Raptor Pharmaceutical Corp. ("Raptor" or the "Company"), today announced the publication of results from a Phase 2a clinical trial of a prototype formulation of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has been granted Certificate of Good Manufacturing Practice (GMP) compliance for its cell therapy manufacturing facility in Besançon, France.
› Verified 7 days ago